Literature DB >> 3877075

Clinically significant cross-reactions with counterimmunoelectrophoresis between pneumococcus type 6 and Haemophilus influenzae type b.

T L Ballard, A Spangler, M H Roe, M P Glode.   

Abstract

Biologically and clinically significant cross-reactions may occur between the immunochemically similar capsule antigens of Haemophilus influenzae type b and Streptococcus pneumoniae type 6 by using counterimmunoelectrophoresis (CIE). In three cases of culture-proven S. pneumoniae type 6 disease, a false-positive H. influenzae type b CIE result was detected in a body fluid. Two of three cases were also positive when tested by CIE with pneumococcal omnisera. However, in one of the culture-proven cases of pneumococcal type 6 disease, the omniserum was negative and only the burro 132 H. influenzae type b antiserum demonstrated a positive precipitant reaction. In addition to the three case isolates, we evaluated nine blood or cerebrospinal fluid isolates of pneumococcus type 6, using a variety of both species- and type-specific antisera, by CIE. Two burro antisera detected 12 of 12 (100%) of the S. pneumoniae type 6 strains. A rabbit H. influenzae type b antiserum did not detect any (0 of 12; 0%) of the S. pneumoniae type 6 strains evaluated. All (12 of 12; 100%) of the S. pneumoniae type 6 strains were detected with both rabbit omniserum (S. pneumoniae) and rabbit type 6 antiserum. Our data illustrate the importance of being aware of the immunologic cross-reactivity of the H. influenzae type b capsule with the pneumococcus type 6 capsule and the possibility of false-positive results with CIE when patient specimens are interpreted.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877075      PMCID: PMC268520          DOI: 10.1128/jcm.22.5.754-756.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Polyribophosphate, the type-specific substance of Hemophilus influenzae, type b.

Authors:  S ZAMENHOF; G LEIDY; P L FITZGERALD; H E ALEXANDER; E CHARGAFF
Journal:  J Biol Chem       Date:  1953-08       Impact factor: 5.157

2.  Further studies on polyribophosphate.

Authors:  E ROSENBERG; S ZAMENHOF
Journal:  J Biol Chem       Date:  1961-11       Impact factor: 5.157

3.  Studies on haemophilus influenzae type characteristics.

Authors:  G TUNEVALL
Journal:  Acta Pathol Microbiol Scand       Date:  1952

4.  Latex agglutination in diagnosis of bacterial infections, with special reference to patients with meningitis and septicemia.

Authors:  J Kaldor; R Asznowicz; D G Buist
Journal:  Am J Clin Pathol       Date:  1977-08       Impact factor: 2.493

5.  Practical considerations in using counterimmunoelectrophoresis to identify the principal causative agents of bacterial meningitis.

Authors:  C A Finch; H W Wilkinson
Journal:  J Clin Microbiol       Date:  1979-10       Impact factor: 5.948

6.  Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b.

Authors:  M W Bradshaw; R Schneerson; J C Parke; J B Robbins
Journal:  Lancet       Date:  1971-05-29       Impact factor: 79.321

7.  Polyribitol-phosphate: an antigen of four gram-positive bacteria cross-reactive with the capsular polysaccharide of haemophilus influenzae type B.

Authors:  M Argaman; T Y Liu; J B Robbins
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

8.  Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria.

Authors:  J B Robbins; R Schneerson; M P Glode; W Vann; M S Schiffer; T Y Liu; J C Parke; C Huntley
Journal:  J Allergy Clin Immunol       Date:  1975-08       Impact factor: 10.793

9.  An Escherichia coli antigen cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b: occurrence among known serotypes, and immunochemical and biologic properties of E. coli antisera toward H. influenzae type b.

Authors:  R Schneerson; M Bradshaw; J K Whisnant; R L Myerowitz; J C Parke; J B Robbins
Journal:  J Immunol       Date:  1972-06       Impact factor: 5.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.